Literature DB >> 4245998

The response of ponies to Myxovirus influenzae A-equi 2. I. Serum and nasal antibody titres following exposure.

B T Rouse, W J Ditchfield.   

Abstract

The antibody response in serum and nasal secretions of groups of ponies vaccinated or infected with Myxovirus influenzae A-equi 2 was examined. Following infection by aerosol with live virus, a weak antibody response was recorded in both serum and secretions. Antibody levels were undetectable in secretions at 31 days after infection. After primary intramuscular vaccination with killed virus, using sodium alginate as an adjuvant, antibody was detected only in the serum. However, following revaccination, a pronounced antibody response was demonstrated in both serum and secretions. Antibody was still detectable in all four ponies when tested 135 days later. Only a serum antibody response was detected in ponies after primary intramuscular vaccination with a commercial vaccine. Upon revaccination nasal antibody occurred in all ponies but this only persisted for about 30 days. Neither serum nor nasal antibody response occurred following intranasal vaccination and revaccination with a killed virus vaccine.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4245998      PMCID: PMC1319411     

Source DB:  PubMed          Journal:  Can J Comp Med        ISSN: 0008-4050


  17 in total

1.  The influence of the route of administration of Newcastle disease virus on host response. II. Studies on artificial passive immunity.

Authors:  C W Beard; B C Easterday
Journal:  J Infect Dis       Date:  1967-02       Impact factor: 5.226

2.  Immunoglobulins in serum and nasal secretions following infection with type 1 parainfluenza virus and injection of inactivated vaccines.

Authors:  C B Smith; J A Bellanti; R M Chanock
Journal:  J Immunol       Date:  1967-07       Impact factor: 5.422

3.  Poliovirus antibody response in serum and nasal secretions following intranasal inoculation with inactivated poliovaccine.

Authors:  P L Ogra; D T Karzon
Journal:  J Immunol       Date:  1969-01       Impact factor: 5.422

4.  Protective effect of antibody to parainfluenza type 1 virus.

Authors:  C B Smith; R H Purcell; J A Bellanti; R M Chanock
Journal:  N Engl J Med       Date:  1966-11-24       Impact factor: 91.245

5.  The role of nasal secretion and serum antibody in the rhinovirus common cold.

Authors:  T R Cate; R D Rossen; R G Douglas; W T Butler; R B Couch
Journal:  Am J Epidemiol       Date:  1966-09       Impact factor: 4.897

Review 6.  Secretory immunoglobulins.

Authors:  T B Tomasi; J Bienenstock
Journal:  Adv Immunol       Date:  1968       Impact factor: 3.543

7.  Comments on the immunology of equine influenza.

Authors:  J D Todd
Journal:  J Am Vet Med Assoc       Date:  1969-07-15       Impact factor: 1.936

8.  Improved measurement of influenza virus hemagglutinin titer.

Authors:  G L Miller
Journal:  J Immunol       Date:  1965-08       Impact factor: 5.422

9.  Use of sodium alginate adjuvant in immunization against equine influenza.

Authors:  I L Shechmeister; T Aeschliman; W G Kammlade
Journal:  Am J Vet Res       Date:  1967-09       Impact factor: 1.156

10.  ZBITNEW A: UPPER RESPIRATORY DISEASE IN THOUROUGHBRED HORSES: STUDIES OF ITS VIRAL ETIOLOGY IN THE TORONTO AREA, 1960 TO 1963.

Authors:  J DITCHFIELD; L W MACPHERSON
Journal:  Can J Comp Med Vet Sci       Date:  1965-01
View more
  3 in total

1.  Influenza infection in ferrets: role of serum antibody in protection and recovery.

Authors:  P A Small; R H Waldman; J C Bruno; G E Gifford
Journal:  Infect Immun       Date:  1976-02       Impact factor: 3.441

Review 2.  A Review on Equine Influenza from a Human Influenza Perspective.

Authors:  Fleur Whitlock; Pablo R Murcia; J Richard Newton
Journal:  Viruses       Date:  2022-06-15       Impact factor: 5.818

3.  Specific antibody in the equine genital tract following systemic and local immunization.

Authors:  P R Widders; C R Stokes; J S David; F J Bourne
Journal:  Immunology       Date:  1985-04       Impact factor: 7.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.